Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Salesforce Inc (CRM) vs Invesco Ltd. (IVZ) Price & Performance

Salesforce IncTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Salesforce Inc vs Invesco Ltd. — how do they compare? Salesforce Inc trades at $193.25 (market cap $161.73B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Salesforce Inc is far larger — about 11.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.

CRMIVZ
Market Cap
$161.73B$13.85B
Sector
TechnologyFinancials
52-Week High
$266.23$32.01
52-Week Low
$150.12$20.67
Enterprise Value
$191.77B$24.01B
Dividend Yield
0.89%2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Salesforce Inc

Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) amid recent market volatility. The stock maintains strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show bullish momentum with support at $196 and resistance at $199, though RSI levels suggest potential overbought conditions. Recent news highlights AI-driven growth opportunities but also sector-wide software stock pressures.

CRM presents a compelling investment case with analyst consensus pointing to 17% upside to the $230.83 price target. Strong cash flow generation ($13.09B operating cash flow) and AI monetization progress support growth, but risks include competitive AI landscape and macroeconomic sensitivity affecting software demand. Institutional sentiment remains positive with 75.78% buy ratings.

Invesco Ltd.

Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.

The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Salesforce Inc

Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.

Read more on CRM

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ